tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Dumont FJ et al. | Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. | 1990 | J. Immunol. | pmid:1688572 |
| Woo J et al. | Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. | 1990 | Clin. Exp. Immunol. | pmid:1689226 |
| Dumont FJ et al. | The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. | 1990 | J. Immunol. | pmid:1689353 |
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Ueda Y et al. | Induction of graft acceptance after dog kidney or liver transplantation. | 1990 | Transplant. Proc. | pmid:1689909 |
| Ohara K et al. | Toxicologic evaluation of FK 506. | 1990 | Transplant. Proc. | pmid:1689910 |
| Nalesnik MA et al. | The effect of FK 506 and CyA on the Lewis rat renal ischemia model. | 1990 | Transplant. Proc. | pmid:1689911 |
| Morris RE et al. | A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. | 1990 | Transplant. Proc. | pmid:1697111 |
| Woo J et al. | Flow cytometric analysis of lymphocyte populations and activation antigen expression in blood and lymphoid tissues of FK 506-treated rats. | 1990 | Transplant. Proc. | pmid:1697112 |
| Woo J et al. | Effects of FK 506 and low concentration cyclosporine on human lymphocyte activation antigen expression: a flow cytometric analysis. | 1990 | Transplant. Proc. | pmid:1697113 |
| Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
| Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
| Fung JJ et al. | Overview of FK506 in transplantation. | 1990 | Clin Transpl | pmid:1715740 |
| Collier SJ | Immunosuppressive drugs. | 1989-1990 | Curr. Opin. Immunol. | pmid:2484794 |
| McCauley J et al. | Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. | 1989 Dec 23-30 | Lancet | pmid:2481200 |
| Takabayashi K et al. | Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. | 1989 | Clin. Immunol. Immunopathol. | pmid:2466594 |
| Morris RE et al. | Immunopharmacology of FK-506. | 1989 | Transplant. Proc. | pmid:2468201 |
| Thomson AW and Woo J | Immunosuppressive properties of FK-506 and rapamycin. | 1989 | Lancet | pmid:2474733 |
| Todo S et al. | Renal transplantation in baboons under FK 506. | 1989 | Surgery | pmid:2474865 |
| Kay JE et al. | Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. | 1989 | Immunology | pmid:2475433 |